报价延迟最少15分钟:2025/11/07 05:38 EST
盘前时段
|
||||
|
24.18 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
24.33
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-7.51/-7.22
|
|
企业价值
9.91B
|
| 资产负债 |
|
每股账面净值
24.06
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
3.20B
|
|
每股收益
23.27
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/11/07 05:38 EST
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases. |
